An analyst from Needham raised the price target significantly from $210 to $235 and maintained a Buy rating. The upgrade is based on positive clinical data from the HERIZON-GEA-01 study, which showed favorable results for the company's treatment across all subgroups. Additionally, the company sold a Priority Review Voucher for $200 million and is targeting business deals in 2026.